ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL191
CHEMBL191
Compound Name LOSARTAN
ChEMBL Synonyms Hyzaar | DUP 753 | LOSARTAN POTASSIUM | LOSAPREX | LOSARTAN | COZAAR
Max Phase 4 (Approved)
Trade Names COZAAR | LOSARTAN POTASSIUM | LOSAPREX
Molecular Formula C22H23ClN6O

Additional synonyms for CHEMBL191 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES CCCCc1nc(Cl)c(CO)n1Cc2ccc(cc2)c3ccccc3c4nnn[nH]4
Standard InChI InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13- ...
Download InChI
Standard InChI Key PSIFNNKUMBGKDQ-UHFFFAOYSA-N

Sources

  • British National Formulary
  • DrugMatrix
  • Orange Book
  • PubChem BioAssays
  • Scientific Literature
  • TP-search Transporter Database
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL191

Molecule Features

CHEMBL191 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:Y First In Class:N Chirality:Achiral Molecule Prodrug:N Oral:Y Parenteral:N Topical:N Black Box:Y Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Type-1 angiotensin II receptor antagonist Type-1 angiotensin II receptor DailyMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
AgingD000375GO:0007568aging1ClinicalTrials
Constriction, PathologicD003251EFO:0006818stricture1ClinicalTrials
Diabetic NephropathiesD003928EFO:0000401diabetic nephropathy3ClinicalTrials
Kidney DiseasesD007674EFO:0003086kidney disease1ClinicalTrials
Non-alcoholic Fatty Liver DiseaseD065626EFO:1001249non-alcoholic steatohepatitis3ClinicalTrials
HypertensionD006973EFO:0000537hypertension3ClinicalTrials
ClinicalTrials
Heart FailureD006333EFO:0003144heart failure3ClinicalTrials
GlioblastomaD005909EFO:0000519glioblastoma multiforme3ClinicalTrials
HIV InfectionsD015658EFO:0000764HIV infection2ClinicalTrials
Renal Insufficiency, ChronicD051436EFO:0003884chronic kidney disease3ClinicalTrials
Eosinophilic EsophagitisD057765EFO:0004232eosinophilic esophagitis2ClinicalTrials
Marfan SyndromeD008382Orphanet:558Marfan syndrome3ClinicalTrials
ClinicalTrials
Diabetic RetinopathyD003930EFO:0003770diabetic retinopathy2ClinicalTrials
Hypertension, PulmonaryD006976EFO:0001361pulmonary hypertension3ClinicalTrials
SarcopeniaD055948EFO:1000653sarcopenia2ClinicalTrials
Cystic FibrosisD003550Orphanet:586Cystic fibrosis2ClinicalTrials
Diabetes Mellitus, Type 1D003922EFO:0001359type I diabetes mellitus2ClinicalTrials
InflammationD007249MP:0001845inflammation2ClinicalTrials
Pancreatic NeoplasmsD010190EFO:0002618pancreatic carcinoma2ClinicalTrials
Peripheral Arterial DiseaseD058729EFO:0004265peripheral arterial disease0ClinicalTrials
Essential HypertensionD000075222EFO:1002032primary hypertension3ClinicalTrials
ClinicalTrials
ProteinuriaD011507HP:0000093Proteinuria3ClinicalTrials
ClinicalTrials
Glomerulonephritis, IGAD005922EFO:0004194IGA glomerulonephritis3ClinicalTrials
Multiple SclerosisD009103EFO:0003885multiple sclerosis1ClinicalTrials
Idiopathic Pulmonary FibrosisD054990EFO:0000768idiopathic pulmonary fibrosis2ClinicalTrials
Anemia, Sickle CellD000755Orphanet:232Sickle cell anemia0ClinicalTrials
Cardiomyopathy, HypertrophicD002312EFO:0000538hypertrophic cardiomyopathy2ClinicalTrials
Cardiovascular DiseasesD002318EFO:0000319cardiovascular disease4ATC
ClinicalTrials
Glomerulosclerosis, Focal SegmentalD005923EFO:0004236focal segmental glomerulosclerosis2ClinicalTrials
Hyperoxaluria, PrimaryD006960Orphanet:416Primary hyperoxaluria3ClinicalTrials
Stress Disorders, Post-TraumaticD013313EFO:0001358post-traumatic stress disorder2ClinicalTrials
Wounds and InjuriesD014947EFO:0000546injury1ClinicalTrials

Clinical Data

ClinicalTrials.gov LOSARTAN
The Cochrane Collaboration LOSARTAN

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL191. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL227 Type-1 angiotensin II receptor Homo sapiens 1.000
CHEMBL263 Type-1B angiotensin II receptor Rattus norvegicus 1.000
CHEMBL4607 Angiotensin II type 2 (AT-2) receptor Homo sapiens 1.000
CHEMBL3374 Angiotensin II type 1a (AT-1a) receptor Bos taurus 1.000
CHEMBL3948 Angiotensin II type 1a (AT-1a) receptor Oryctolagus cuniculus 1.000
CHEMBL329 Type-1A angiotensin II receptor Rattus norvegicus 1.000
CHEMBL1671613 Type-1 angiotensin II receptor Cavia porcellus 1.000
CHEMBL257 Angiotensin II type 2 (AT-2) receptor Rattus norvegicus 1.000



10uM


ChEMBL_ID Target Name Organism Score
CHEMBL227 Type-1 angiotensin II receptor Homo sapiens 1.000
CHEMBL257 Angiotensin II type 2 (AT-2) receptor Rattus norvegicus 1.000
CHEMBL263 Type-1B angiotensin II receptor Rattus norvegicus 1.000
CHEMBL4607 Angiotensin II type 2 (AT-2) receptor Homo sapiens 1.000
CHEMBL3374 Angiotensin II type 1a (AT-1a) receptor Bos taurus 1.000
CHEMBL3948 Angiotensin II type 1a (AT-1a) receptor Oryctolagus cuniculus 1.000
CHEMBL329 Type-1A angiotensin II receptor Rattus norvegicus 1.000
CHEMBL1671613 Type-1 angiotensin II receptor Cavia porcellus 1.000
CHEMBL3721 Cytochrome P450 2C8 Homo sapiens 0.996

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
422.9 422.1622 4.27 8 92.51 ACID


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
6 2 0 7 2 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
4.15 4.39 3.46 1.48 4 30 0.44

Structural Alerts

There are no structural alerts for CHEMBL191

Compound Cross References

ATC C - CARDIOVASCULAR SYSTEM
C09 - AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C09C - ANGIOTENSIN II ANTAGONISTS, PLAIN
C09CA - Angiotensin II antagonists, plain
C09CA01 - losartan

ChemSpider ChemSpider:PSIFNNKUMBGKDQ-UHFFFAOYSA-N
DailyMed losartan potassium
PubChem SID: 144204988 SID: 170465135 SID: 26748956
Wikipedia Losartan

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL191



ACToR 114798-26-4
BindingDB 82258
Brenda 8734
ChEBI 6541
ChemicalBook CB8120081
DrugBank DB00678
DrugCentral 1610
eMolecules 601417
EPA CompTox Dashboard DTXSID7023227
FDA SRS JMS50MPO89
Guide to Pharmacology 3941 590
Human Metabolome Database HMDB0014816
IBM Patent System 50C3CBF625FF7C086F3D403E3D4403C0 4053DEC01DC27818C5E5C0F21C433186 6A338D6D1BCBAF055FCC19FFCF4A4420
KEGG Ligand C07072
LINCS LSM-3701
Mcule MCULE-5204931675
MolPort MolPort-006-167-607 MolPort-003-666-553
Nikkaji J276.444J
PDBe LSN
PharmGKB PA450268
PubChem 3961
PubChem: Thomson Pharma 14880416 14758375
SureChEMBL SCHEMBL60
ZINC ZINC000003873160

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/PSIFNNKUMBGKDQ-UHFFFAOYSA-N spacer
spacer